Assessment of metabolic phenotypes in patients with non-ischemic dilated cardiomyopathy undergoing cardiac resynchronization therapy

Journal of Cardiovascular Translational Research

Volumn 3, Issue 6, 2010, Pages 643-651

  Obrzut, Sebastian ^a,b   Tiongson, Jay ^a   Jamshidi, Neema ^a   Phan, Huy Minh ^a   Hoh, Carl ^a   Birgersdotter Green, Ulrika ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; Fatty acids; Metabolism

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID; BIOLOGICAL MARKER; FATTY ACID; LACTIC ACID; OXYGEN; PYRUVIC ACID;

ADULT; AGED; ARTICLE; BLOOD; CARDIAC RESYNCHRONIZATION THERAPY; CONGESTIVE CARDIOMYOPATHY; ENERGY METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEART MUSCLE; HEART STROKE VOLUME; HUMAN; MALE; METABOLISM; MIDDLE AGED; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHENOTYPE; PROSPECTIVE STUDY; PROTEOMICS; TIME; TREATMENT FAILURE;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY, DILATED; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FEMALE; HEART FAILURE; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXYGEN; OXYGEN CONSUMPTION; PHENOTYPE; PROSPECTIVE STUDIES; PROTEOMICS; PYRUVIC ACID; STROKE VOLUME; TIME FACTORS; TREATMENT FAILURE; VENTRICULAR FUNCTION, LEFT;

EID: 79952837133     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-010-9223-5     Document Type: Article

References (37)

1. Cleland, J. G., Daubert, J. C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., et al. (2005). Cardiac resynchronization-heart failure (CARE-HF) study investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England Journal of Medicine, 352, 1539-1549 [PubMed: 15753115]. (Pubitemid 40517094)
2. Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., et al. (2004). Comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) investigators. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. The New England Journal of Medicine, 350, 2140-2150 [PubMed: 15152059].
3. St John Sutton, M. G., Plappert, T., Abraham, W. T., Smith, A. L., DeLurgio, D. B., Leon, A. R., et al. (2003). Multicenter insync randomized clinical evaluation (MIRACLE) study group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation, 107, 1985-1990 [PubMed: 12668512]. (Pubitemid 36506071)
4. Abraham, W. T., Young, J. B., León, A. R., Adler, S., Bank, A. J., Hall, S. A., et al. (2004). Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation, 110, 2864-2868 [PubMed: 15505095]. (Pubitemid 39473610)
5. Saxon, L. A., & Ellenbogen, K. A. (2003). Resynchronization therapy for the treatment of heart failure. Circulation, 108, 1044-1048 [PubMed: 12952826]. (Pubitemid 37071511)
6. Beshai, J. F., Grimm, R. A., Nagueh, S. F., Baker, J. H., 2, Beau, S. L., Greenberg, S. M., et al. (2007). RethinQ Study Investigators. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. The New England Journal of Medicine, 357, 2461-2471 [PubMed: 17986493]. (Pubitemid 350272785)
7. Chung, E. S., Leon, A. R., Tavazzi, L., Sun, J. P., Nihoyannopoulos, P., Merlino, J., et al. (2008). Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation, 117, 2608-2616 [PubMed: 18458170].
8. Abraham, T., Kass, D., Tonti, G., Tomassoni, G. F., Abraham, W. T., Bax, J. J., et al. (2009). Imaging cardiac resynchronization therapy. JACC Cardiovascular Imaging, 2, 486-497 [PubMed: 19580733].
9. Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005). Myocardial substrate metabolism in the normal and failing heart. Physiological Reviews, 85, 1093-1129 [PubMed: 15987803]. (Pubitemid 40894649)
10. Lommi, J., Kupari, M., & Yki-Järvinen, H. (1998). Free fatty acid kinetics and oxidation in congestive heart failure. The American Journal of Cardiology, 81, 45-50 [PubMed: 9462605]. (Pubitemid 28046841)
11. Taylor, M., Wallhaus, T. R., Degrado, T. R., Russell, D. C., Stanko, P., Nickles, R. J., et al. (2001). An evaluation of myocardial fatty acid and glucose uptake using PET with [18F] fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure. Journal of Nuclear Medicine, 42, 55-62 [PubMed: 11197981]. (Pubitemid 32104778)
12. Paolisso, G., Gambardella, A., Galzerano, D., D'Amore, A., Rubino, P., Verza, M., et al. (1994). Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism, 43, 174-179 [PubMed: 8121298]. (Pubitemid 24061849)
13. Rosenblatt-Velin, N., Montessuit, C., Papageorgiou, I., Terrand, J., & Lerch, R. (2001). Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. Cardiovascular Research, 52, 407-416 [PubMed: 11738057]. (Pubitemid 33153103)
14. Barger, P. M., & Kelly, D. P. (1999). Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. The American Journal of the Medical Sciences, 318, 36-42 [PubMed: 10408759]. (Pubitemid 30387273)
15. Sack, M. N., Rader, T. A., Park, S., Bastin, J., McCune, S. A., & Kelly, D. P. (1996). Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation, 94, 2837-2842 [PubMed: 8941110]. (Pubitemid 26411749)
16. Dávila-Román, V. G., Vedala, G., Herrero, P., de las Fuentes, L., Rogers, J. G., Kelly, D. P., et al. (2002). Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 40, 271-277 [PubMed: 12106931]. (Pubitemid 34756287)
17. Ramakrishna, R., Edwards, J. S., McCulloch, A., & Palsson, B. O. (2001). Flux-balance analysis of mitochondrial energy metabolism: consequences of systemic stoichiometric constraints. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 280, R695-R704 [PubMed: 11171647].
18. Burkhoff, D., Weiss, R. G., Schulman, S. P., Kalil-Filho, R., Wannenburg, T., & Gerstenblith, G. (1991). Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. The American Journal of Physiology, 261, H741-H750 [PubMed: 1887921].
19. Korvald, C., Elvenes, O. P., & Myrmel, T. (2000). Myocardial substrate metabolism influences left ventricular energetics in vivo. American Journal of Physiology. Heart and Circulatory Physiology, 278, H1345-H1351 [PubMed: 10749732]. (Pubitemid 30235514)
20. Lammerant, J., Huynh-Thu, T., & Kolanowski, J. (1985). Inhibitory effects of the D(-)isomer of 3-hydroxybutyrate on cardiac non-esterified fatty acid uptake and oxygen demand induced by norepinephrine in the intact dog. Journal of Molecular and Cellular Cardiology, 17, 421-433 [PubMed: 3894678].
21. Mjos, O. D. (1971). Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. The Journal of Clinical Investigation, 50, 1386-1389 [PubMed: 5090055].
22. Vanky, F. B., Hakanson, E., Szabó, Z., Jorfeldt, L., & Svedjeholm, R. (2006). Myocardial metabolism before and after valve replacement for aortic stenosis. Journal of Cardiovascular Surgery (Torino), 47, 305-313 [PubMed: 16760867]. (Pubitemid 44043967)
23. Vo, T. D., Greenberg, H. J., & Palsson, B. O. (2004). Reconstruction and functional characterization of the human mitochondrial metabolic network based on proteomic and biochemical data. The Journal of Biological Chemistry, 279, 39532-39540 [PubMed: 15205464]. (Pubitemid 39258220)
24. Lee, D. Y., Yun, H., Park, S., & Lee, S. Y. (2003). MetaFluxNet: the management of metabolic reaction information and quantitative metabolic flux analysis. Bioinformatics, 19, 2144-2146 [PubMed: 14594721]. (Pubitemid 37408167)
25. Bridge, P. D., & Sawilowsky, S. S. (1999). Increasing physicians' awareness of the impact of statistics on research outcomes: comparative power of the t test and Wilcoxon Rank-Sum test in small samples applied research. Journal of Clinical Epidemiology, 52, 229-235 [PubMed: 10210240]. (Pubitemid 29148434)
26. Metz, C. E., Herman, B. A., & Shen, J. H. (1998). Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data. Statistics in Medicine, 17, 1033-1053 [PubMed: 9612889]. (Pubitemid 28203832)
27. Kates, A. M., Herrero, P., Dence, C., Soto, P., Srinivasan, M., Delano, D. G., et al. (2003). Impact of aging on substrate metabolism by the human heart. Journal of the American College of Cardiology, 41, 293-299 [PubMed: 12535825]. (Pubitemid 36092200)
28. Kjekshus, J. K., & Mjos, O. D. (1972). Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. The Journal of Clinical Investigation, 51, 1767-1776 [PubMed: 5032525].
29. Mjos, O. D., Kjekshus, J. K., & Lekven, J. (1974). Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. The Journal of Clinical Investigation, 53, 1290-1299 [PubMed: 4825226].
30. Simonsen, S., & Kjekshus, J. K. (1978). The effect of free fatty acids on myocardial oxygen consumption during atrial pacing and catecholamine infusion in man. Circulation, 58, 484-491 [PubMed: 679439]. (Pubitemid 9006976)
31. Mjös, O. D., & Kjekshus, J. (1971). Increased local metabolic rate by free fatty acids in the intact dog heart. Scandinavian Journal of Clinical and Laboratory Investigation, 28, 389-393 [PubMed: 5157041].
32. Sabbah, H. N., Chandler, M. P., Mishima, T., Suzuki, G., Chaudhry, P., Nass, O., et al. (2002). Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. Journal of Cardiac Failure, 8, 416-422 [PubMed: 12528095]. (Pubitemid 36055744)
33. Chandler, M. P., Stanley, W. C., Morita, H., Suzuki, G., Roth, B. A., Blackburn, B., et al. (2002). Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circulation Research, 91, 278-280 [PubMed: 12193459]. (Pubitemid 34976992)
34. Wallhaus, T. R., Taylor, M., DeGrado, T. R., Russell, D. C., Stanko, P., Nickles, R. J., et al. (2001). Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation, 103, 2441-2446 [PubMed: 11369683]. (Pubitemid 32493369)
35. Kates, A. M., Herrero, P., Dence, C., Soto, P., Srinivasan, M., Delano, D. G., et al. (2003). Impact of aging on substrate metabolism by the human heart. Journal of the American College of Cardiology, 41, 293-299 [PubMed: 12535825]. (Pubitemid 36092200)
36. Wisneski, J. A., Gertz, E. W., Neese, R. A., & Mayr, M. (1987). Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. The Journal of Clinical Investigation, 79(2), 359-366 [PubMed: 3805273]. (Pubitemid 17009666)
37. Nellis, S. H., Liedtke, A. J., & Renstrom, B. (1992). Fatty acid kinetics in aerobic myocardium: characteristics of tracer carbon entry and washout and influence of metabolic demand. Journal of Nuclear Medicine, 33(10), 1864-1874 [PubMed: 1403160].